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Introduction: The polymer PEI-MP (polyethyleneiminomethyl phosphonic acid) 
might be labelled with 99mTc. It was initially synthesized for palliative therapy of 
bone metastases after convenient radiolabelling, however in biodistribution studies 
performed with different PEI-MP/radionuclides, was obvious that the bladder wall 
was a target organ [1-3], demonstrating a certain selectivity to bladder cells, and 
so, to bladder cancer cells. The aim of this study was to evaluate the efficacy of 
99mTc-PEI-MP for diagnosis of bladder carcinoma, evaluating in vitro and in vivo the 
biokinetics and biodistribution of 99mTc-PEI-MP.  
Material and Methods: The radiochemical purity of 99mTc-PEI-MP was achieved 
using ascending microchromatography (ITLC-SG/acetone and W3MM/citrate1M). In 
order to determine the hydrophilicity or lipophilicity of 99mTc-PEI-MP, it was 
determined the partition coefficient, after radiolabelling. Cellular uptake and 
retention studies were performed using the LigandTracer instrument after add 
99mTc-PEI-MP or Na99mTcO4 (control) to the culture medium of a petri dish with the 
cells. Subsequently, the radioactivity uptake and retained by cells was determined 
over time. The in vivo studies were performed using 4 groups of balb/c nu/nu mice: 
2 normal injected with Na99mTcO4 (control) and 99mTc-PEI-MP and 2 with bladder 
carcinoma xenotransplants injected with the same complexes. After injection, were 
acquired dynamic and static images for 2 and 4h. For biodistribution proposes, mice 
were euthanized after the static images and organ samples where weighted and 
 
  
  
  
 
 
 
 
 
counted in a well-counter to obtain percentage injected activity per gram of organ 
(%ID/g).  
Results: The radiochemical purity of 99mTc-PEI-MP was ≥90%. The n-octanol/water 
partition coefficient was negative during time, demonstrating that 99mTc-PEI-MP is a 
hydrophilic complex. The in vitro uptake and retention studies demonstrated that 
the uptake was higher for 99mTc-PEI-MP in relation to their control and that the 
retention is stable and high. The biodistribution with 99mTc-PEI-MP showed that the 
excretion of these complexes occurs primarily through the renal system. 
Tumour/muscle ratio for 99mTc-PEI-MP was >1. Tumour/bladder, tumour/bone, 
tumour/liver and tumour/lungs ratios were always <0.5. 
Conclusions: 99mTc-PEI-MP seems to be optimal for diagnosis of bladder cancer 
and its metastasis. The results demonstrated that 99mTc-PEI-MP is a hydrophilic 
complex and therefore water soluble, being expected that in vivo the excretion 
occurred by the renal system. These results were confirmed by in vivo imaging and 
ex vivo biodistribution studies. The uptake by the tumour was always superior to 1, 
and therefore it could be an advantage in determine the level of invasion to the 
muscle involving the bladder and to support the surgery. The uptake by the bone, 
liver and lungs was high comparing with the tumour uptake, and therefore in case 
of distant metastases the mass would appear as a cold lesion. References: [1] 
Dormehl IC et al: Biodistribution and pharmacokinetics of variously sized molecular 
radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker 
for therapy in the normal primate model. Arzneimittel-Forschung 2001,51(3):258-
263; [2] Botelho MF et al: Dosimetric evaluation of the polyphosphonate; PEI-MP 
labelled with 117mSn, 186Re and 99mTc as potential diagnosis/therapeutic bone 
agents. European journal of nuclear medicine and molecular imaging 
2006,33:S309. 
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